NasdaqGM - Delayed Quote USD

Sagimet Biosciences Inc. (SGMT)

4.2400

-0.2000

(-4.50%)

At close: 4:00 PM EDT

4.2100

-0.03

(-0.71%)

After hours: 5:31 PM EDT

Key Events

Loading Chart for SGMT

9/21 12:03 PM

DELL

Previous Close 4.4400
Open 4.5600
Bid 4.2200 x 200
Ask 4.2900 x 400
Day's Range 4.2400 - 4.5900
52 Week Range 2.1300 - 20.7100
Volume 336,019
Avg. Volume 779,480
Market Cap (intraday) 135.315M
Beta (5Y Monthly) --
PE Ratio (TTM) --
EPS (TTM) -2.6600
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 40.00

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

www.sagimet.com

8

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SGMT

21.77%

S&P 500

9.47%

1-Year Return

SGMT

--

S&P 500

15.45%

3-Year Return

SGMT

--

S&P 500

15.45%

5-Year Return

SGMT

--

S&P 500

15.45%

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Sagimet Biosciences Inc.

4.2400

-4.50%

Mkt Cap 135.315M

Industry Biotechnology

Sutro Biopharma, Inc.

4.2300

+1.93%

Mkt Cap 345.865M

Industry Biotechnology

8.70

-0.11%

Mkt Cap 855.941M

Industry Biotechnology

2.6400

-2.58%

Mkt Cap 127.001M

Industry Biotechnology

Terns Pharmaceuticals, Inc.

5.89

+5.94%

Mkt Cap 380.935M

Industry Biotechnology

Viridian Therapeutics, Inc.

14.34

+3.17%

Mkt Cap 915.215M

Industry Biotechnology

Aligos Therapeutics, Inc.

0.6846

-6.26%

Mkt Cap 53.474M

Industry Biotechnology

Edgewise Therapeutics, Inc.

17.48

-4.64%

Mkt Cap 1.633B

Industry Biotechnology

2seventy bio, Inc.

4.4900

+2.51%

Mkt Cap 230.808M

Industry Biotechnology

Intensity Therapeutics, Inc.

4.0000

0.00%

Mkt Cap 54.838M

Industry Biotechnology

ALX Oncology Holdings Inc.

15.61

-3.70%

Mkt Cap 788.286M

Industry Biotechnology

Valuation Measures

As of 5/10/2024

Market Cap

141.70M
Enterprise Value

46.87M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

50.83
Price/Book (mrq)

1.56
Enterprise Value/Revenue

--
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-29.61%
Return on Equity (ttm)

-46.96%
Revenue (ttm)

2M
Net Income Avi to Common (ttm)

-27.88M
Diluted EPS (ttm)

-2.6600

Balance Sheet and Cash Flow

Total Cash (mrq)

94.9M
Total Debt/Equity (mrq)

0.07%
Levered Free Cash Flow (ttm)

-15.08M

SGMT does not have Company Insights

LBPH Longboard Pharmaceuticals, Inc.

19.93

-0.94%

INTS Intensity Therapeutics, Inc.

4.0000

0.00%

SLRN Acelyrin, Inc.

4.6900

+0.21%

CADL Candel Therapeutics, Inc.

10.20

+9.44%

ZJYL Jin Medical International Ltd.

3.3200

-4.05%

CING Cingulate Inc.

0.7909

+3.24%

SERA Sera Prognostics, Inc.

9.10

-1.73%

NEXI NexImmune, Inc.

3.4100

-3.94%

ZVSA ZyVersa Therapeutics, Inc.

5.46

+1.68%

IVVD Invivyd, Inc.

2.3700

+4.87%

MGIH Millennium Group International Holdings Limited

1.4600

-1.35%

INAB IN8bio, Inc.

1.0200

+0.99%

AIMD Ainos, Inc.

1.0600

-0.93%

LAES SEALSQ Corp

1.1900

0.00%

MINM Minim, Inc.

4.0700

+5.99%

BDRX Biodexa Pharmaceuticals Plc

0.9685

+4.44%